China's biggest biopharmaceutical company has reported a sharp rise in annual profits, according to the latest figures from the Chinese government. Rising revenues have been driven by strong growth, but investors are increasing their dividends.
Source: prnewswire.comPublished on 2023-03-22
Related news
- With increased accountability for ESG , how can lawyers best advise clients ?
- Sustainability 101 : Greenwashing
- Greenpeace : Social media the new battle ground for climate disinformation by brands
- How to lower IT digital carbon footprint
- As a user , you should be able to control your footprint .
- Klépierre : 2022 FULL - YEAR EARNINGS
- ESG , the acronym in search of a fashion makeover
- Green Muni Bonds Are Blooming Slowly
- Consumers are being misled by green investments , warns City watchdog
- Was COP26 A Good Deal for Brazil ?
- First Veto Issued by President Biden Protecting ESG Investing
- Green financing future trends | Mining News
- Carbon markets dont have to fail - Bulletin of the Atomic Scientists
- Responsible investing : Switching your super more effective than buying an electric car
- Green hushing explained why brands are cutting back on sustainability marketing